Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Portal Therapeutics receives FDA orphan, fast track designations for PORT-77
PORT-77, in Phase II development, aims to reduce PPIX efflux from red blood cells and hepatocytes, limiting liver damage. Credit: Testalize.me on Unsplash.
PORT-77, in Phase II development, aims to reduce PPIX efflux from red blood cells and hepatocytes, limiting liver damage. Credit: Testalize.me on Unsplash.